We Give Our Utmost Care to

Better Safeguard Patients’ Health

Our Dedication to Patients is Reflected in Every Detail in Manufacturing and Operations
Generic Name:
Enoxaparin sodium injection
Target Market:
EU countries
2,000 IU (20 mg)/0.2 mL 4,000 IU (40 mg)/0.4 mL 6,000 IU (60 mg)/0.6 mL 8,000 IU (80 mg)/0.8 mL 10,000 IU (100 mg)/1.0 mL 12,000 IU (120 mg)/0.8 mL 15,000 IU (150 mg)/1 mL 30,000 IU (300 mg)/3 mL 50,000 IU (500 mg)/5 mL 100,000 IU (1000 mg)/10 mL
Inhixa is indicated in adults for:

·Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.

·Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.

·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.

·Acute coronary syndrome:

·Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

·Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).